Posts
Plasma therapy is a type of therapy where a patient is given a
thin, clear tube of fluid filled with a solution of either saline or potassium
chloride. This fluid is pumped into the vein through the vein's valve and blood
is supplied back to the heart via the blood vessel. These techniques are used
for patients who have had their entire blood drained for other purposes like
dialysis treatment. This method is used to restore the damaged cells in the
blood so that they can function properly again and be able to fight infection
better.
Convalescent Plasma Therapy or CRT as it is commonly called is a
procedure that is very similar to a blood transfusion where a vein is punctured
in order to replace a portion of the patient's blood with a clean, clear, high
quality plasma. In most cases, this is used after chemotherapy or when the body
is suffering from organ transplant rejection. The most common reason for
undergoing this type of therapy is in patients who have been left with a
certain level of immunity loss that may be due to a disease that has taken
place within the body. In other cases, the patient may have suffered from liver
failure, which leaves them without the ability to manufacture the antibodies
needed to battle infections.
Market Dynamics
Emergence of Covid-19 is expected to propel growth of the global
plasma therapy market. For instance, globally, as of 10:44 am CET, 23
November 2020, there have been 58,229,138 confirmed cases of COVID-19,
including 1,382,106 deaths, reported to the World Health Organization.
Moreover, increasing adoption of PRP is also expected to aid in
growth of the global plasma therapy market. For instance, according to the
American Society of Plastic Surgeons (ASPS), platelet-rich plasma (PRP)
treatment is estimated to increase by 12% from nearly 113,356 procedures in
2017 to approximately 127,394 procedures in 2018.
Recommendations against the use of platelet-rich plasma (PRP) injections
for the treatment of hip and knee osteoarthritis are expected to hinder growth
of the global plasma therapy market. For instance, in January 2020, American
College of Rheumatology, in partnership with the Arthritis Foundation, released
the 2019 ACR/AF Guideline for the Management of Osteoarthritis of the Hand, Hip
and Knee, which recommended against the use of PRP injections for the treatment
of hip and knee osteoarthritis.
Competitive Analysis
Major players operating in the global plasma therapy market
include, Octapharma AG, China Biologic Products Holdings, Inc. Bio Products
Laboratory Ltd, Kedrion S.p.A , Grifols, S.A., CSL, Biotest AG., Takeda
Pharmaceutical Company Limited., DePuy Synthes, Regen Lab SA, LFB SA., and
Immunotek Bio Centers
November 2020: GC Pharma, a South Korea-based biotech company,
initiated additional production of its plasma therapy treatment for the Covid-19
amid growing demand for treatment purposes.
No comments:
Post a Comment